Abstract
Transcatheter aortic valve replacement has become an acceptable alternative to surgical aortic valve replacement in patients who are intermediate to high risk for surgery. The Lotus ™ valve system (Boston Scientific, MA, USA) is an unique, mechanically expanded device. The system includes a braided nitinol frame and an adaptive seal to minimize paravalvular regurgitation. REPRISE III illustrated that among high-risk patients the use of the Lotus valve compared with a self-expanding valve did not result in inferior outcomes for the primary safety end point or the primary effectiveness end point. Future investigation of the Lotus valve system includes the use in low to intermediate risk patients with aortic stenosis as well as those with bicuspid aortic valves and mitral annular calcification.
Original language | English (US) |
---|---|
Pages (from-to) | 367-373 |
Number of pages | 7 |
Journal | Future Cardiology |
Volume | 14 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2018 |
Keywords
- Lotus valve
- REPRISE
- aortic stenosis
- mechanical expansion
- paravalvular leak
ASJC Scopus subject areas
- Molecular Medicine
- Cardiology and Cardiovascular Medicine